Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma?

Barr ML, Jilaveanu LB, Camp RL, Adeniran AJ, Kluger HM, Shuch B.

J Clin Pathol. 2015 Jan;68(1):12-7. doi: 10.1136/jclinpath-2014-202259. Epub 2014 Oct 14.

2.

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma.

Giesen E, Jilaveanu LB, Parisi F, Kluger Y, Camp RL, Kluger HM.

Oncotarget. 2014 Jul 30;5(14):5209-17.

3.

Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma.

Aziz SA, Sznol JA, Albiges L, Zito C, Jilaveanu LB, Camp RL, Escudier B, Kluger HM.

Cancer Cell Int. 2014 Jan 14;14(1):4. doi: 10.1186/1475-2867-14-4.

4.

Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors.

Aziz SA, Sznol JA, Adeniran A, Parisi F, Kluger Y, Camp RL, Kluger HM.

BMC Clin Pathol. 2013 Feb 1;13:3. doi: 10.1186/1472-6890-13-3.

5.

Vascularity of primary and metastatic renal cell carcinoma specimens.

Aziz SA, Sznol J, Adeniran A, Colberg JW, Camp RL, Kluger HM.

J Transl Med. 2013 Jan 14;11:15. doi: 10.1186/1479-5876-11-15.

6.

c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.

Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM.

Ann Oncol. 2013 Feb;24(2):343-9. doi: 10.1093/annonc/mds463. Epub 2012 Sep 28.

7.

Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer.

Agarwal S, Gertler FB, Balsamo M, Condeelis JS, Camp RL, Xue X, Lin J, Rohan TE, Rimm DL.

Breast Cancer Res. 2012 Sep 12;14(5):R124. doi: 10.1186/bcr3318.

8.

CD70 expression patterns in renal cell carcinoma.

Jilaveanu LB, Sznol J, Aziz SA, Duchen D, Kluger HM, Camp RL.

Hum Pathol. 2012 Sep;43(9):1394-9. doi: 10.1016/j.humpath.2011.10.014. Epub 2012 Mar 7.

9.

Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome.

Lazova R, Camp RL, Klump V, Siddiqui SF, Amaravadi RK, Pawelek JM.

Clin Cancer Res. 2012 Jan 15;18(2):370-9. doi: 10.1158/1078-0432.CCR-11-1282. Epub 2011 Nov 11.

10.

Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts.

Baquero MT, Lostritto K, Gustavson MD, Bassi KA, Appia F, Camp RL, Molinaro AM, Harris LN, Rimm DL.

Breast Cancer Res. 2011 Nov 2;13(5):R85. doi: 10.1186/bcr2937.

11.

Lymph node ratio should be considered for incorporation into staging for breast cancer.

Chagpar AB, Camp RL, Rimm DL.

Ann Surg Oncol. 2011 Oct;18(11):3143-8. doi: 10.1245/s10434-011-2012-9. Epub 2011 Aug 17.

PMID:
21847696
12.

Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables.

Bai Y, Tolles J, Cheng H, Siddiqui S, Gopinath A, Pectasides E, Camp RL, Rimm DL, Molinaro AM.

Lab Invest. 2011 Aug;91(8):1253-61. doi: 10.1038/labinvest.2011.75. Epub 2011 Apr 25.

13.

In vitro studies of dasatinib, its targets and predictors of sensitivity.

Jilaveanu LB, Zito CR, Aziz SA, Chakraborty A, Davies MA, Camp RL, Rimm DL, Dudek A, Sznol M, Kluger HM.

Pigment Cell Melanoma Res. 2011 Apr;24(2):386-9. doi: 10.1111/j.1755-148X.2011.00835.x. No abstract available.

14.

Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.

Aziz SA, Jilaveanu LB, Zito C, Camp RL, Rimm DL, Conrad P, Kluger HM.

Clin Cancer Res. 2010 Dec 15;16(24):6029-39. doi: 10.1158/1078-0432.CCR-10-1490.

15.

Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models.

Parisi F, Gonzalez AM, Nadler Y, Camp RL, Rimm DL, Kluger HM, Kluger Y.

Breast Cancer Res. 2010;12(5):R66. doi: 10.1186/bcr2633. Epub 2010 Sep 1.

16.

Automated analysis of tissue microarrays.

Dolled-Filhart M, Gustavson M, Camp RL, Rimm DL, Tonkinson JL, Christiansen J.

Methods Mol Biol. 2010;664:151-62. doi: 10.1007/978-1-60761-806-5_15.

PMID:
20690061
17.

In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis.

Neumeister V, Agarwal S, Bordeaux J, Camp RL, Rimm DL.

Am J Pathol. 2010 May;176(5):2131-8. doi: 10.2353/ajpath.2010.090712. Epub 2010 Mar 12.

18.

The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development.

Kidd M, Siddique ZL, Drozdov I, Gustafsson BI, Camp RL, Black JW, Boyce M, Modlin IM.

Regul Pept. 2010 Jun 8;162(1-3):52-60. doi: 10.1016/j.regpep.2010.01.009. Epub 2010 Feb 6.

PMID:
20144901
19.

Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.

Mehnert JM, McCarthy MM, Jilaveanu L, Flaherty KT, Aziz S, Camp RL, Rimm DL, Kluger HM.

Hum Pathol. 2010 Mar;41(3):375-84. doi: 10.1016/j.humpath.2009.08.016. Epub 2009 Dec 11.

20.

Melanoma prognostic model using tissue microarrays and genetic algorithms.

Gould Rothberg BE, Berger AJ, Molinaro AM, Subtil A, Krauthammer MO, Camp RL, Bradley WR, Ariyan S, Kluger HM, Rimm DL.

J Clin Oncol. 2009 Dec 1;27(34):5772-80. doi: 10.1200/JCO.2009.22.8239. Epub 2009 Nov 2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk